Natera Inc (NTRA) — Titan Protect Analysis

NTRA

Natera Inc

Healthcare · ·

$215.31

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$30.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-613.40

Based on estimated future earnings — lower means cheaper

Rev Growth

+38.8%

Year-over-year revenue change

Profit Margin

-9.1%

How much profit the company keeps from each dollar of revenue

ROE

-15.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$267.50

+24% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 18 analysts covering this stock

About Natera Inc

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provi

https://www.natera.com

Country: United States Employees: 6,135 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.998

Good returns relative to risk taken

Kelly Fraction

0.0837

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.485

Returns exceed worst-case losses — strong risk profile

Annual Return

41.9%

Historical annualised return based on price data

Max Drawdown

-28.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.57

Significantly more volatile than the market

52W High

$256.36

16% below the year high

52W Low

$131.81

63% above the year low

Avg Volume

1,433,993

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.62

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

13.53

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

65.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-12.4%

Profit from core operations before interest and tax

Free Cash Flow

$137M

Positive — the business generates more cash than it spends

Revenue (TTM)

$2.5B

Total revenue over the last 12 months

Net Income

$-226,315,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$300.00

Target Median

$267.50

Target Low

$193.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
30 Apr2026	Dave McCormick	Republican	sell	500K–1M

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go